Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster

Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster

Peer Reviewed Papers

Case Studies

Oncolines News

Assay Kits

Recent Oncolines News

Case study – Cellular sensitivity to WRN inhibition in colony-forming unit assay2026-09-04T16:25:33+02:00
Case study – Cellular sensitivity to WRN inhibition in colony-forming unit assay

Case study – Cellular sensitivity to WRN inhibition in colony-forming unit assay

Case study – Fluorescence imaging of DNA damage after WRN inhibitor exposure2026-09-04T16:26:36+02:00
Case study – Fluorescence imaging of DNA damage after WRN inhibitor exposure

Case study – Fluorescence imaging of DNA damage after WRN inhibitor exposure

Case study – High TTK expression in uterine corpus endometrial carcinoma2026-09-04T16:27:02+02:00
Case study – High TTK expression in uterine corpus endometrial carcinoma

Case study – High TTK expression in uterine corpus endometrial carcinoma

Case study – Downstream effects of specific TP53 mutations2026-09-04T16:27:31+02:00
Case study – Downstream effects of specific TP53 mutations

Case study – Downstream effects of specific TP53 mutations

Case study – Binding kinetics of TROP2-targeted ADCs and antibodies via ResidenceTimer™2026-09-04T16:28:59+02:00
Case study – Binding kinetics of TROP2-targeted ADCs and antibodies via ResidenceTimer™

Case study – Binding kinetics of TROP2-targeted ADCs and antibodies via ResidenceTimer™

Case study – Prediction of ABC transporter-mediated drug resistance through gene expression analysis2026-09-04T16:29:29+02:00
Case study – Prediction of ABC transporter-mediated drug resistance through gene expression analysis

Case study – Prediction of ABC transporter-mediated drug resistance through gene expression analysis

Case study – PROTAC-induced degradation of cancer immunotherapy target IDO12026-09-04T16:29:56+02:00
Case study – PROTAC-induced degradation of cancer immunotherapy target IDO1

Case study – PROTAC-induced degradation of cancer immunotherapy target IDO1

Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors2026-09-04T16:30:20+02:00
Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors

Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors

Case study – Target validation by combining Oncolines® profiling and gene dependency screens2026-09-04T16:30:52+02:00
Case study – Target validation by combining Oncolines® profiling and gene dependency screens

Case study – Target validation by combining Oncolines® profiling and gene dependency screens

Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib2026-09-04T16:31:17+02:00
Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib

Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib

Case study – Target identification via Oncolines® profiling and ResidenceTimer™2026-09-04T16:31:44+02:00
Oncolines Casestudy Target Identification Via Oncolines® Profiling And ResidenceTimer™
Case study – Target identification via Oncolines® profiling and ResidenceTimer™

Case study – Target identification via Oncolines® profiling and ResidenceTimer™

Case study – Gene expression profiling to understand and combat drug resistance2026-09-04T16:32:59+02:00
Case study – Gene expression profiling to understand and combat drug resistance

Case study – Gene expression profiling to understand and combat drug resistance

Case study – Combination matrix to determine Bliss independence synergy scores2026-09-04T16:33:49+02:00
Case study – Combination matrix to determine Bliss independence synergy scores

Case study – Combination matrix to determine Bliss independence synergy scores

Case study – 3D spheroid drug sensitivity2026-09-04T16:34:11+02:00
Case study – 3D spheroid drug sensitivity

Case study – 3D spheroid drug sensitivity

Case study – BTK inhibitor fenebrutinib2026-09-04T16:34:35+02:00
Case study – BTK inhibitor fenebrutinib

Case study – BTK inhibitor fenebrutinib

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer2026-09-07T13:16:03+02:00
Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Case study – Synergistic interaction of olaparib and cisplatin2026-09-04T16:35:37+02:00
Case study – Synergistic interaction of olaparib and cisplatin

Case study – Synergistic interaction of olaparib and cisplatin

Case study – TTK patient stratification marker2026-09-04T16:36:29+02:00
Case study – TTK patient stratification marker

Case study – TTK patient stratification marker

Case study – MEK inhibitor2024-11-19T12:54:57+01:00
Case study – MEK inhibitor

Case study – MEK inhibitor

Case study – Arginase-1 Inhibitors2026-09-04T16:36:55+02:00
Case study – Arginase-1 Inhibitors

Case study – Arginase-1 Inhibitors

Case study – Kadcyla®2024-11-19T12:57:31+01:00
Case study – Kadcyla®

Case study – Kadcyla®

Case study – Characterization of TTK Inhibitors2026-09-04T16:37:25+02:00
Case study – Characterization of TTK Inhibitors

Case study – Characterization of TTK Inhibitors

Case study – CDK4/62024-11-19T13:15:49+01:00
Case study – CDK4/6

Case study – CDK4/6

Case study – BTK Inhibitor ibrutinib2026-09-04T16:37:49+02:00
Case study – BTK Inhibitor ibrutinib

Case study – BTK Inhibitor ibrutinib

Premium Benefits of Oncolines Precision Medicine Services: Cell-Based Assays, Drug Combinations, High-Throughput Screening

  • Integration of cancer biology and big data analysis

  • Identification of patient selection markers

  • Side-by-side comparison with known anti-cancer agents

  • Discovery of targeted and novel synergistic drug combinations

  • Science-driven technology platforms

  • Short turnaround times

How may we help you?